SP 17001
Alternative Names: SP17001Latest Information Update: 28 Nov 2021
At a glance
- Originator Spherium Biomed
- Class Small molecules; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for clinical-Phase-Unknown development in Vascular-disorders in Spain (PO)
- 25 Oct 2018 Clinical trials in Vascular disorders (aortic aneurysm) in Spain (PO) (Spherium Biomed pipeline, October 2018)
- 25 Oct 2018 Spherium Biomed plans a clinical trial for Vascular disorders (aortic aneurysm in patients with Marfan syndrome) in 2021 (Spherium Biomed pipeline, October 2018)